Abstract Number: 1897 • 2015 ACR/ARHP Annual Meeting
Fragmented Qrs Patterns Do Not Correlate with the Degree of Lung and Skin Involvement in Patients with Systemic Sclerosis
Background/Purpose: Cardiac involvement is a common subclinical feature of systemic sclerosis (SSc) and results from the widespread fibrosis observed during disease course. Fragmented QRS (fQRS)…Abstract Number: 2360 • 2015 ACR/ARHP Annual Meeting
The Effectiveness of Tacrolimus in Patients with Interstitial Lung Disease Secondary to Autoimmune Disease
Background/Purpose: Interstitial lung disease (ILD) secondary to connective tissue disease (CTD) is most commonly seen in systemic sclerosis followed by polymyositis and dermatomyositis. Anti-synthetase syndrome…Abstract Number: 1273 • 2014 ACR/ARHP Annual Meeting
Assessment of the Effect of Rituximab in the Treatment of Interstitial Lung Disease associated with the Antisynthetase Syndrome
Background/purpose: To assess clinical outcomes including pulmonary function and radiographic imaging in patients with ILD and the antisynthetase syndrome who were treated with Rituxan (RTX)Methods:…Abstract Number: 1272 • 2014 ACR/ARHP Annual Meeting
Myositis-Specific and Myositis Associated Autoantibodies in Indian Patients with Inflammatory Myositis
Background/Purpose Recently, idiopathic inflammatory myositis (IIM) has been categorised into distinct subsets based on myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA). However, there is…Abstract Number: 432 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors for Disease Progression
Background/Purpose Rheumatoid arthritis (RA) is the most common systemic connective tissue disease in the U.S. Interstitial lung disease (ILD) is a frequent extra-articular manifestation of…Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting
Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…Abstract Number: 2976 • 2014 ACR/ARHP Annual Meeting
Lung Ultrasound Screening for Interstitial Lung Disease in Rheumatoid Arthritis. Comparison with Usual Detection Algorithms in Clinical Practice
Background/Purpose: interstitial lung disease (RA-ILD) is one of the most serious extraarticular complications of rheumatoid arthritis (RA). Presently, it is not clear which is the…Abstract Number: 2697 • 2014 ACR/ARHP Annual Meeting
Gender Disparities in Lung Transplantation in Patients with Systemic Sclerosis-Related Interstitial Lung Disease and Pulmonary Hypertension
Background/Purpose: Lung transplantation is often the most viable option for patients with severe systemic sclerosis (SSc)-associated interstitial lung disease (ILD) that is unresponsive to pharmacologic…Abstract Number: 2190 • 2014 ACR/ARHP Annual Meeting
Features of Interstitial Lung Disease Associated with Connective Tissue Disease in a Spanish Southwest Cohort
Background/Purpose Diffuse interstitial lung disease (ILD) can be associated with connective tissue diseases (CTD), and can increase morbidity and mortality significantly. The predominant patterns of…Abstract Number: 1797 • 2014 ACR/ARHP Annual Meeting
One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study
Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease…Abstract Number: 1784 • 2014 ACR/ARHP Annual Meeting
Prognostic Factors for Interstitial Lung Disease with Microscopic Polyangiitis
Background/Purpose Many patients with interstitial lung disease (ILD) complicated by microscopic polyangiitis (MPA) show a UIP pattern on chest CT. The prognosis is poorer than…Abstract Number: 1685 • 2014 ACR/ARHP Annual Meeting
Effects of Mycophenolate Mofetil on Pulmonary Lung Function in Interstitial Lung Disease of Systemic Sclerosis
Background/Purpose: Interstitial lung disease remains a primary driver of morbidity and mortality in patients suffering from systemic sclerosis. Cyclophosphamide currently is the treatment with the…Abstract Number: 1684 • 2014 ACR/ARHP Annual Meeting
Treatment of Scleroderma Associated Lung Disease with Mycophenolate Mofetil: A Community-Based Study
Background/Purpose: Interstitial lung disease occurs in over 80% of patients with scleroderma. Cyclophosphamide is the only treatment proven to benefit scleroderma lung disease in a…Abstract Number: 1698 • 2014 ACR/ARHP Annual Meeting
Peripheral Blood Eosinophil Counts Increase in Patients with Systemic Sclerosis and Associated with Its Disease Severity
Background/Purpose : Increased levels of serum pro-fibrotic cytokines such as IL-4 and IL-13 and plasma CXCL4 have been previously reported in patients with systemic sclerosis…Abstract Number: 1682 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is common and when progressive, associated with significant morbidity and mortality. Cyclophosphamide is frequently used as first line…
ACR Meeting Abstracts